We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Board of Directors of Orion Corporation has decided to change the subscription periods of the company's Stock Option Plan 2001 so that the share subscription period for the full plan will end on 31 May 2006.
Germany's new Christian Democrat and Social Democrat coalition government is planning to cut pharmaceutical spending in the country by EUR8bn (US$9.41bn) next year, according to local reports.
Despite a recent drive by the Chinese government to provide free antiretrovirals (ARVs), HIV/AIDS sufferers in the country are being forced to pay for treatment because of excessive profiteering in the healthcare system, according to a report in the Washington Post.
Overseas sales of Israeli medicines reached US$1.49bn for the first nine months of 2005, according to official statistics, as the country's generic and primarily export-driven pharmaceutical industry grew from strength to strength.
Cuba has exported pharmaceuticals worth US$300mn so far this year, making drugs the second most important commodity in the country's US$2bn export market behind nickel.
Dr. Reddy's Laboratories Limited announced on Tuesday that it has has entered into a definitive agreement to acquire Roche's API business at the state-of-the-art manufacturing site in Cuernavaca, Mexico including all employees and business supply contracts.
Sanofi-Aventis beat third-quarter forecasts as the French pharmaceuticals company's older heart disease and cancer drugs, as well as influenza vaccines continued to sell well.
Astellas Pharma Inc., Japan's second -- largest drugmaker, bought the right to test, make and sell an antibiotic called telavancin from Theravance Inc., a U.S. drugmaker.
Greer, a leading developer and provider of allergenic source materials and allergy immunotherapy products, is expanding its global reach and commitment to next-generation allergy care through a partnership with Danish biotechnology company Curalogic.
ChemDiv, Inc. of San Diego, CA, and ProQinase GmbH of Freiburg, Germany, announced that they have signed an agreement to establish a partnership in the discovery and preclinical development of new kinase inhibitors.